Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target

Benzinga · 2d ago
Barclays analyst Glen Santangelo reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and announces $110 price target.